NCT01811823View on ClinicalTrials.gov

Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults

PHASE4CompletedINTERVENTIONAL
Enrollment

301

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

November 20, 2014

Study Completion Date

November 20, 2014

Conditions
InfluenzaHIVTuberculosis
Interventions
BIOLOGICAL

Trivalent Inactivated Influenza Vaccine

"The study vaccine will be the seasonal 2013 un-adjuvanted TIV which is provided as a 0•5 milliliter suspension of split virus mixture of 15 micrograms each of circulating H1N1- like strain, H3N2- like strain and B - like strain.~The WHO recommended vaccine formulation for Southern Hemisphere 2013 Influenza Season contains the following influenza strains:~* A/California/7/2009 (H1N1)pdm-like virus~* A/Victoria/361/2011 (H3N2)-like virus~* B/Wisconsin/1/2010-like virus. (Yamagata lineage)"

Trial Locations (1)

2013

Respiratory and Meningeal Pathogens research unit, Johannesburg

All Listed Sponsors
lead

University of Witwatersrand, South Africa

OTHER

NCT01811823 - Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults | Biotech Hunter | Biotech Hunter